Amylyx Pharmaceuticals (AMLX) shares moved after the company reported second quarter 2026 results, which showed a net loss of US$43.42 million and basic loss per share from continuing operations of US$0.39.

The latest earnings update appears to have sharpened attention on Amylyx Pharmaceuticals, with the share price at US$24.19 and a 1-day share price return of 10.71%, building on a 30-day share price return of 33.13% and a 1-year total shareholder return of 208.55% that points to strong momentum.

If you are interested in how other healthcare stocks with AI exposure are moving after earnings and trial updates, it could be a good time to review 42 healthcare AI stocks

For Amylyx Pharmaceuticals, such a strong recent run after reporting continued losses raises a clear tension between enthusiasm for its pipeline and a reset in expectations. The next step is to see how that aligns with valuation.

Most Popular Narrative: 5.3% Undervalued

The most followed narrative currently sees Amylyx Pharmaceuticals trading a little below its fair value of $25.56 compared with the last close at $24.19, which puts the focus squarely on what is driving that gap.

The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.

Want to understand why this fair value leans on a single late stage trial and a future margin profile more typical of established pharma companies rather than early stage biotechs? The valuation hinges on a specific revenue ramp, a shift from current losses to positive earnings, and a P/E multiple usually reserved for fast growing franchises. Curious how those ingredients are combined and discounted at just over 7% to arrive at $25.56? The full narrative lays out the exact assumptions and timing that connect Amylyx Pharmaceuticals' pipeline today to that future price tag.

Result: Fair Value of $25.56 (UNDERVALUED)

However, Amylyx Pharmaceuticals remains heavily reliant on a single Phase 3 LUCIDITY readout and on its existing cash to fund multiple trials, so setbacks on either front could quickly challenge this undervalued narrative.

Another View on Amylyx Pharmaceuticals Valuation

The earlier fair value for Amylyx Pharmaceuticals leaned on analyst earnings forecasts. A different lens is its current P/B ratio of 9.8x compared with 7.4x for peers and 2.6x for the broader US Pharmaceuticals industry, which points to a rich valuation. Is this premium a cushion or a risk if expectations change?

Next Steps

With both risks and rewards in focus for Amylyx Pharmaceuticals, it makes sense to move quickly and stress test the narrative against your own expectations using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Amylyx Pharmaceuticals?

If Amylyx Pharmaceuticals has caught your attention, do not stop there. Use Simply Wall Street's screeners to quickly spot other stocks that might fit your approach.

• Target potential mispricings by reviewing companies that appear to trade below fair value using the 49 high quality undervalued stocks.
• Prioritise resilience by scanning for businesses that score well on balance sheet strength with the solid balance sheet and fundamentals stocks screener (49 results).
• Get ahead of the crowd by checking a screener containing 19 high quality undiscovered gems before attention and liquidity potentially move elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.